Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- Mitophagy level by flow cytometry
Study Overview
Brief Summary
Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming.
A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method.
This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •- Person who provides oral consent
- •- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation
- •Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation
- •No coronary lesion
- •No peripheral arterial disease (limbs, carotids, aortic aneurysm)
Exclusion Criteria
- •Person not affiliated with national health care system
- •Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
- •Person under a legal protection measure (curatorship, guardianship, tutorship)
- •Pregnant, parturient or breastfeeding women
- •Major unable to express consent
Arms & Interventions
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
Intervention: Blood samples (Biological)
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
Intervention: myocardial tissue samples (Procedure)
Atheromatous coronary patients
patients scheduled for coronary artery bypass surgery with extracorporeal circulation
Intervention: Data collection (Other)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
Intervention: Blood samples (Biological)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
Intervention: myocardial tissue samples (Procedure)
Non-atheratomous patients
Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease
Intervention: Data collection (Other)
Outcomes
Primary Outcomes
Mitophagy level by flow cytometry
Time Frame: Before the introduction of extracorporeal circulation.
Average fluorescence corresponding to PINK1-AF488 intracellular labelling (mitophagy checkpoint) in conventional (CD33+, CD66b-, CD14++, CD16-), intermediate (CD33+, CD66-, CD14++, CD16+), or non-conventional (CD33+, CD66b-, CD14+, CD16++) monocytes.
Secondary Outcomes
No secondary outcomes reported